Skip to content

Impact of the 5E rehabilitation model on self-management in women with stress urinary incontinence: a mixed study

Impact of the 5E rehabilitation model on self-management in women with stress urinary incontinence: a mixed study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071673
Enrollment
Unknown
Registered
2023-05-22
Start date
2023-05-31
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress urinary incontinence

Interventions

Control group:Routine care measures for stress urinary incontinence
Intervention group:Self-management measures based on the 5E rehabilitation model

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Women older than 18 years of age and younger than 70 years of age (2) Mild to moderate stress urinary incontinence as diagnosed by a physician (Using the Ingelman-Sundberg indexing method) (3)The patient agrees not to use any treatment (drug or other form) known to affect lower urinary tract function throughout treatment and follow-up; (4) Voluntary participation in this study and signed informed consent form

Exclusion criteria

Exclusion criteria: (1) within 3 months after pelvic surgery; (2) Severe SUI (Ingelman-Sundberg scale method) (3) People who cannot use smart phones and have disabilities in listening, speaking, reading and writing; (4) Patients with a history of urinary incontinence surgery or pelvic floor surgery within 6 months before the trial; (5) Diagnosed with vesicoureteral reflux, pelvic organ or vaginal prolapse stage II or above; The presence of malformations that cause urinary incontinence; (6) Patients with acute reproductive and urinary system infection within one week and not cured; (7) Used midodine hydrochloride, tolterodine, vaginal local estrogen and other drugs for urinary incontinence within 1 week before the test; (8) Uncontrolled diabetes, multiple sclerosis, stroke, Parkinson's disease, spinal cord injury, cauda equina nerve injury, multisystem atrophy, mental disorders (depression, anxiety, etc.) and other systemic diseases that may affect the function of the lower urinary tract; (9) Participated in other drug clinical trials or device clinical trials and used test drugs or devices within 3 months before the test; (10) Diagnosed patients with cervical cancer and precancerous lesions; (11) Previous history of drug use and drug abuse (12) Those who are considered unsuitable for the study by the researcher;

Design outcomes

Primary

MeasureTime frame
Amount of urine leakage;International Consultationon Incontinenee Questionnaire-Short Form;Broome pelvic muscle self-efficacy scale, BPMSES;

Secondary

MeasureTime frame
stress urinary incontinence knowledge questionnaire;pelvic floor muscle training compliance questionnaire;urinary incontinence impact questionnaire short form ;

Countries

China

Contacts

Public ContactYAN Xin

The First Hospital of Shanxi Medical University

xinyan6712@sina.com+86 351 463 0923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026